YI Qiusha 1,2,3,4 , YANG Chunsong 1,2,3 , ZENG Linan 1,2,3 , CHEN Lina 6 , QIAO Lina 7 , HUANG Liang 1,2,3 , SONG Haoxin 1,2,3,5 , LIN Mao 1,2,3,5 , LI Wenrui 1,2,3,5 , MI Xue 1,2,3,4 , ZHANG Lingli 1,2,3
  • 1. Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, 610041, P.R.China;
  • 2. Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, 610041, P.R.China;
  • 3. Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, 610041, P.R.China;
  • 4. West China School of Medicine, Sichuan University, Chengdu, 610041, P.R.China;
  • 5. West China School of Pharmacy, Sichuan University, Chengdu, 610041, P.R.China;
  • 6. Department of Pediatric Respiratory Immunology, West China Second University Hospital, Sichuan University, Chengdu, 610041, P.R.China;
  • 7. Department of Pediatric Intensive Care Unit, West China Second University Hospital, Sichuan University, Chengdu, 610041, P.R.China;
ZHANG Lingli, Email: zhanglingli@scu.edu.cn
Export PDF Favorites Scan Get Citation

Objective To systematically review the efficacy of pidotimod in children.Methods PubMed, The Cochrane Library, EMbase, CNKI, CBM, VIP and WanFang Data databases were searched online to collect randomized controlled trials (RCTs) on pidotimod in children from inception to January, 2018. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies, then, meta-analysis was performed by using RevMan 5.3 software.Results A total of 310 RCTs involving 30 525 children were included. The results of meta-analysis showed that, compared with conventional therapy, conventional therapy combined with pidotimod could not improve the efficacy of children with respiratory infections (RR=1.78, 95%CI 0.99 to 3.20, P>0.05). However, pidotimod could significantly reduce the number of respiratory tract infection (MD=−2.79, 95%CI −3.12 to −2.46, P<0.05), shorten the time of respiratory tract infection (MD=−4.15, 95%CI −4.72 to −3.58, P<0.05), and the time of fever (MD=−1.47, 95%CI −1.77 to −1.17, P<0.05) in recurrent respiratory tract infection. Pidotimod could also reduce the time of fever (MD=−0.90, 95%CI −1.60 to −0.20, P<0.05) in children with mycoplasma pneumoniae pneumonia, the time of fever (MD=−1.51, 95%CI −1.91 to −1.11, P<0.05) in children with hand-foot-mouth disease, and reduce the incidence of anaphylactoid purpura followed up for 6 months (RR=0.42, 95%CI 0.30 to 0.61, P<0.05) in children with anaphylactoid purpura. However, there was no significant difference between two groups in the recurrence of asthma for 1 year follow-up (RR=0.80, 95%CI 0.60 to 1.06, P>0.05).Conclusion Current evidence shows that pidotimod may be effective for children with respiratory tract infection, asthma, hand-foot-mouth disease, could reduce disease relapse and relieve symptoms related to illness.

Citation: YI Qiusha, YANG Chunsong, ZENG Linan, CHEN Lina, QIAO Lina, HUANG Liang, SONG Haoxin, LIN Mao, LI Wenrui, MI Xue, ZHANG Lingli. Efficacy of pidotimod in children: a systematic review based on 310 RCTs. Chinese Journal of Evidence-Based Medicine, 2019, 19(5): 571-577. doi: 10.7507/1672-2531.201810058 Copy

  • Previous Article

    Efficacy and safety of 1 470 nm laser vaporization vs. transurethral resection of prostate for benign prostatic hyperplasia: a meta-analysis
  • Next Article

    Efficacy of resorbable membrane and non-resorbable membrane in dental implant to guide bone regeneration: a meta-analysis